NASDAQ:IONS Ionis Pharmaceuticals (IONS) Stock Price, News & Analysis $35.63 +0.04 (+0.11%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Ionis Pharmaceuticals Stock (NASDAQ:IONS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ionis Pharmaceuticals alerts:Sign Up Key Stats Today's Range$35.05▼$36.4050-Day Range$33.73▼$40.3652-Week Range$33.33▼$54.44Volume4.06 million shsAverage Volume1.36 million shsMarket Capitalization$5.63 billionP/E RatioN/ADividend YieldN/APrice Target$60.65Consensus RatingModerate Buy Company OverviewIonis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Read More… Ionis Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks89th Percentile Overall ScoreIONS MarketRank™: Ionis Pharmaceuticals scored higher than 89% of companies evaluated by MarketBeat, and ranked 122nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingIonis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.68, and is based on 12 buy ratings, 5 hold ratings, and 1 sell rating.Amount of Analyst CoverageIonis Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ionis Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to remain at ($3.37) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is -14.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is -14.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 13.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.18% of the float of Ionis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIonis Pharmaceuticals has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Ionis Pharmaceuticals has recently decreased by 5.43%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.0 / 5Environmental Score-3.58 Percentage of Shares Shorted7.18% of the float of Ionis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIonis Pharmaceuticals has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Ionis Pharmaceuticals has recently decreased by 5.43%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.79 News SentimentIonis Pharmaceuticals has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Ionis Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest19 people have searched for IONS on MarketBeat in the last 30 days. This is an increase of 280% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Ionis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $299,578.00 in company stock.Percentage Held by InsidersOnly 2.71% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions93.86% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ionis Pharmaceuticals' insider trading history. Receive IONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IONS Stock News HeadlinesIonis Pharmaceuticals (IONS) Announces FDA Approval of Tryngolza™ for Treatment of Familial Chylomicronemia SyndromeDecember 22 at 4:13 AM | americanbankingnews.comIonis stock rises following FDA approval of TRYNGOLZADecember 21 at 12:40 PM | ca.investing.comCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.December 22, 2024 | Brownstone Research (Ad)Ionis gets FDA approval for TryngolzaDecember 21 at 12:15 AM | msn.comThe Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 6 ExpertsDecember 21 at 12:15 AM | benzinga.comTRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to dietDecember 19 at 6:28 PM | prnewswire.comUS FDA approves Ionis Pharma's genetic disorder drugDecember 19 at 5:18 PM | reuters.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Sees Significant Decline in Short InterestDecember 18, 2024 | americanbankingnews.comSee More Headlines IONS Stock Analysis - Frequently Asked Questions How have IONS shares performed this year? Ionis Pharmaceuticals' stock was trading at $50.59 at the beginning of the year. Since then, IONS stock has decreased by 29.6% and is now trading at $35.63. View the best growth stocks for 2024 here. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its quarterly earnings results on Thursday, August, 1st. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.47. Ionis Pharmaceuticals's revenue was up 19.7% on a year-over-year basis. Who are Ionis Pharmaceuticals' major shareholders? Top institutional investors of Ionis Pharmaceuticals include Bellevue Group AG (4.99%), Geode Capital Management LLC (1.69%), Charles Schwab Investment Management Inc. (0.91%) and ARK Investment Management LLC (0.95%). Insiders that own company stock include Brett P Monia, Elizabeth L Hougen, Richard S Geary, B Lynne Parshall, C Frank Bennett, Patrick R O'neil, Eugene Schneider, Brian Birchler, Onaiza Cadoret-Manier, Eric Swayze, Joseph Baroldi, Joseph Klein III and Allene M Diaz. View institutional ownership trends. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ionis Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings8/01/2024Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:IONS CUSIP46433010 CIK874015 Webwww.ionispharma.com Phone(760) 931-9200Fax760-603-2700Employees800Year FoundedN/APrice Target and Rating Average Stock Price Target$60.65 High Stock Price Target$77.00 Low Stock Price Target$37.00 Potential Upside/Downside+70.2%Consensus RatingModerate Buy Rating Score (0-4)2.68 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)($2.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-366,290,000.00 Net Margins-44.58% Pretax Margin-44.31% Return on Equity-88.98% Return on Assets-12.42% Debt Debt-to-Equity Ratio1.86 Current Ratio8.91 Quick Ratio8.82 Sales & Book Value Annual Sales$803.07 million Price / Sales7.01 Cash FlowN/A Price / Cash FlowN/A Book Value$2.70 per share Price / Book13.20Miscellaneous Outstanding Shares157,897,000Free Float153,618,000Market Cap$5.63 billion OptionableOptionable Beta0.35 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (NASDAQ:IONS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.